Compare NEOG & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | MLTX |
|---|---|---|
| Founded | 1981 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1995 | 2020 |
| Metric | NEOG | MLTX |
|---|---|---|
| Price | $9.75 | $19.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $10.67 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.5M |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $894,661,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $479.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.56 | $5.95 |
| 52 Week High | $11.43 | $62.75 |
| Indicator | NEOG | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 53.56 |
| Support Level | $8.82 | $15.54 |
| Resistance Level | $10.30 | $21.00 |
| Average True Range (ATR) | 0.41 | 0.88 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 92.98 | 45.74 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.